

February 29, 2024

Contents

Problem Groups 2
 Additions 2
 Problems 3
 Additions 3
 Lab Analytes & Panels 3
 Additions 3
 Updates 4
 Medications 10
 Additions 10
 Updates 10
 Regimen Library 11
 Additions 11
 Added 12
 Updates 12
 Renames 13
 Research 13
 Updates 13
 Billing & HCPCS Codes 16
 Updates 16

Problem Groups

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

BRAF mutation has been updated for **Colon and Rectal Cancers** with the following new documentation point:

- Other BRAF mutation

HER-2/neu Value-IHC is now available for **Ovarian and Primary Peritoneal Cancer** with the following documentation points:

- 0
- 1+
- 2+
- 3+
- Unknown

Insufficient tissue is now available for charting within the following documentation types for **Lung Cancer, Non-Small Cell (NSCLC)**:

- ALK Rearrangement
- BRAF Mutation
- EGFR Expression
- PD-L1
- ROS1

POLD1 mutation is now available for documentation within **Colon and Rectal Cancers** with the following documentation points:

- Wild type
- Mutant
- Unknown

POLE mutation is now available for documentation within **Colon and Rectal Cancers** with the following documentation points:

- Wild type
- Mutant
- Unknown

Problems

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR).

Problem	ICD-10 Codes
DVT of right calf muscular vein	I82.461 - Acute embolism and thrombosis of right calf muscular vein

Lab Analytes & Panels

Additions

KIT D816V testing is diagnostic for Systemic Mastocytosis

The Ontada Medical Office and the US Oncology Network Precision Medicine team have partnered with Clinical Information Services to create a **new lab order** in iKnowMed Generation 2 to encourage physicians to choose the more sensitive digital droplet PCR based KIT D816V test when ordering this type of testing and ask that you include this new test in your iKnowMed lab search options.

- Patients with systemic mastocytosis present with non-descript symptoms including skin lesions, flushing, itching, abdominal pain, diarrhea, nausea, and muscle weakness and can go undiagnosed for many years.
- Many of the KIT D816V tests on the market, including those performed by NGS, are not sensitive enough to detect KIT mutations in peripheral blood, which contributes to the diagnostic delay.
- Based on the data shared from a study conducted by Blueprint Medicines ~50% of patients had a KIT D816V mutation with a variant allele frequency (VAF) <0.1% so we encourage clinical teams to choose one of three test options which can identify mutations below 0.1% VAF.
- The three appropriate test options for high sensitivity KIT testing are:
 - [LabCorp](#)
 - [ARUP](#)
 - [VariantDx](#)

Updates

- 10 color flow cytometry myeloma/monoclonal gammopathy panel
- 10 color plasma cell analysis by flow cytometry report
- 6-methylmercaptapurine riboside, nmol/mL/h
- 6-methylmercaptapurine, nmol/mL/h
- 6-methylthioguanine riboside, nmol/mL/h
- Acid fast bacilli tissue culture panel
- ADAMTS13 inhibitor bethesda titer panel
- AFB culture panel, body fluid
- AFB culture, body fluid
- AFB tissue culture
- AHUS complement interpretation
- AHUS complement panel, serum & plasma
- Alternative compliment path func, S
- Anti SS-A 52 Ab (Ro52) panel
- Anti SS-A 52 Ab (Ro52), ELU/mL
- Anti SS-A 60 Ab (Anti-Ro60), ELU/mL
- Anti SS-A 60 Ab panel
- Antithrombin III panel
- Ascorbic acid, UA, mg/dL
- Atypical hemolytic uremic syndrome complement panel, serum and plasma
- B-Cell lymphoma, FISH, tissue disclaimer
- B-Cell lymphoma, FISH, tissue id
- B-Cell lymphoma, FISH, tissue interpretation
- B-Cell lymphoma, FISH, tissue method
- B-Cell lymphoma, FISH, tissue panel
- B-Cell lymphoma, FISH, tissue reason for referral
- B-Cell lymphoma, FISH, tissue released by
- B-Cell lymphoma, FISH, tissue result
- B-Cell lymphoma, FISH, tissue result summary
- B-Cell lymphoma, FISH, tissue result table
- B-Cell lymphoma, FISH, tissue source
- B-Cell lymphoma, FISH, tissue specimen
- BCR/ABL, P210 quant monitoring panel
- BCR/ABL1 qual w/Rfx to P190 or P210 quant panel
- Beta crosslaps (B CTx) panel
- Beta crosslaps (B CTx), pg/mL
- Bilirubin fractionated panel
- Blastomyces ag panel, urine
- Blastomyces ag, urine
- Blood culture ID, PCR
- Blood culture ID, PCR panel
- Blood culture identification PCR panel
- Blood culture, aerobic/anaerobic panel

- Blood culture, aerobic/anaerobic panel comment
- Body fluid, aerobic culture panel
- Bone marrow analysis, core
- Bone marrow analysis, smears
- Bone marrow analysis, smears panel
- Bone marrow fungus culture
- Bone marrow fungus culture panel
- Bone marrow morphology, clot only panel
- Bone marrow morphology, core only panel
- Bronchial aerobic culture
- Bronchial aerobic culture panel
- Bronchial AFB culture
- Bronchial AFB culture panel
- Bronchial alveolar lavage cell count with differential panel
- Bronchial fungus culture
- Bronchial fungus culture panel
- Bronchial legionella culture
- Bronchial legionella culture panel
- C3, serum
- C4, serum
- C4D complement, P, ug/mL
- CALR Exon 9 final diagnosis
- CALR Exon 9 specimen
- Carboxyhemoglobin, % of total
- Cardiolipin IgG antibody, CU
- Cardiolipin IgM antibody, CU
- Caris assure liquid
- CARIS assure panel
- CBB complement, P, ug/mL
- CCP (cyclic citrullinated peptide) IgG panel, serum
- CCP ab, CU
- Chloride, whole blood, mmol/L
- Chromogranin A, LC/MS/MS, mg/mL
- Chromosome analysis, cyto bone marrow additional method
- Chronic eosinophilic leukemia, FIP1L1-PDGFR α by FISH panel
- Complement, total, serum, quant
- Confirmation, 6 AM, serum, ng/mL
- Coronavirus(229E, HKU1,NL63,OC43) PCR, qual
- COVID-19/influenza A,B molecular
- CP flow interpretation
- CP flow interpretation comment
- Cryptococcal antigen titer
- Cryptococcal antigen, serum panel
- Cytogenetics hold for blood/bone marrow interpretation
- Cytogenetics hold for blood/bone marrow panel

- DAT IgG panel
- DNA extract and hold panel
- DNA extract and hold result
- DNA extraction
- dRVVT mixing panel
- dRVVT ratio panel
- Eculizumab or Ravulizumab taken
- Epithelial cells, fluid(columnar), %
- Factor B complement antigen, S, mg/dL
- Factor H complement antigen, S, mg/dL
- Factor V Leiden reviewed by
- Factor VIII panel
- Factor XIII
- Factor XIII screen panel
- FIP1L1-PDGFR4 by FISH
- FISH, FGFR1, 8p11-12
- FISH, FGFR1, 8p11-12 panel
- Flow cytometry interpretive panel
- Free kappa/lambda light chains panel, urine
- Fungitell assay quant, serum, pg/mL
- Fungitell panel, serum
- Fungitell qual, serum
- Glomerular basement membrane IgG ab panel
- Glucose-6-phosphate dehydrogenase, quant, RBC panel
- Glucose, whole blood, mg/dL
- GTEST PD-L1 28-8 original panel
- GTEST PD-L1 SP263 original panel
- Hematocrit, calculated, %
- Hemoglobin bg, g/dL
- Heparin PF4 ab, qual
- Heparin PF4 ab, qual panel
- Hepatitis B core ab quant, panel
- Hepatitis B surface ab quant, panel
- Hereditary hemochromatosis DNA reviewed by
- Herpes simplex virus (HSV) PCR panel, blood
- Herpes simplex virus (HSV) PCR, qual
- High heparin serotonin release, %
- Histoplasma antibodies CF/ID panel
- Histoplasma antibody immunodiffusion
- Histoplasma antibody mycelial CF (complement fixation)
- Histoplasma antibody yeast CF (complement fixation)
- HIV 1/2 screen (4th generation) panel
- HIV-1 PCR, quant, blood panel
- HU, YO + Ri ab W/ Rfx to titers + WB panel
- IGH somatic hypermutation in B-CLL final diagnosis

- IGH somatic hypermutation in B-CLL panel
- IGH somatic hypermutation in B-CLL result
- IGH somatic hypermutation in B-CLL specimen type
- IHC antibody (2) with interpretation panel
- IHC antibody (3) with interpretation panel
- IHC antibody (4) with interpretation panel
- Immunofixation, urine comment
- Influenza A H3N2V
- Ki-67 (MIB-1), IHC panel
- KIT D816V variant allele frequency, %
- Lactic acid panel, plasma
- Lactic acid, plasma, mmol/L
- Lactic acid, whole blood, mmol/L
- Low heparin serotonin release, %
- Mesothelial/macrophages, body fluid, %
- MRSA DNA amplified probe
- MRSA DNA amplified probe panel
- Myeloma FISH, pre-analysis cell sorting, bone marrow
- Myeloma FISH, pre-analysis cell sorting, bone marrow panel
- Myeloma staging, urine, 24 hr panel
- Myeloma, FISH bm additional information
- Myeloma, FISH bm disclaimer
- Myeloma, FISH bm interpretation
- Myeloma, FISH bm method
- Myeloma, FISH bm reason for referral
- Myeloma, FISH bm result
- Myeloma, FISH bm result summary
- Myeloma, FISH bm result table
- Myeloma, FISH bm specimen
- Myeloma, FISH panel, bone marrow
- Myeloperoxidase ab, CU
- Natura empower comprehensive (2+79) footnotes
- Natura empower comprehensive (2+79) panel
- Natura empower comprehensive (2+79) PDF
- Natura empower comprehensive (2+79) report summary
- Next generation sequencing MRD panel
- NGS for myeloid neoplasms panel
- NGS myeloid neoplasms additional notes
- NGS myeloid neoplasms clinical trials
- NGS myeloid neoplasms disclaimer
- NGS myeloid neoplasms indication for test
- NGS myeloid neoplasms interpretation
- NGS myeloid neoplasms method summary
- NGS myeloid neoplasms NGSSM result
- NGS myeloid neoplasms oncohome panel gene

- NGS myeloid neoplasms pathogenic mutations detected
- NGS myeloid neoplasms reviewed by
- NGS myeloid neoplasms specimen type - 7531
- NGS myeloid neoplasms variants of unknown significance
- Nordiazepam, serum ng/mL
- O2Hb, venous, %
- Oncology chromosome analysis
- Oncology chromosome analysis panel
- OnkoSight Advanced NGS myeloid references 1
- OnkoSight advanced plasma cell myeloma NGS interpretation summary
- OnkoSight advanced plasma cell myeloma NGS methods
- OnkoSight advanced plasma cell myeloma NGS panel
- OnkoSight advanced plasma cell myeloma NGS panel report
- OnkoSight advanced plasma cell myeloma NGS references
- OnkoSight advanced plasma cell myeloma NGS report footer
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR + MPL technical summary
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR detailed genetic interpretation 1
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR interpretation summary
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR methods
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR references 1
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR report footer
- OnkoSight JAK2 V617F Rx JAK2 Exon 12, CALR result
- OnkoSight JAK2 V617F, Rx JAK2 Exon 12, CALR + MPL panel
- OnkoSight JAK2 V617F, Rx JAK2 Exon 12, CALR + MPL panel
- OnkoSight NGS CALR sequencing report
- OnkoSight NGS JAK2 CALR sequencing report
- OnkoSight NGS JAK2 Exon 12 sequencing report
- OnkoSight NGS JAK2 reflex to MPL
- OnkoSight NGS JAK2 reflex to MPL + CALR sequencing panel
- OnkoSight NGS JAK2 reflex to MPL interpretation summary
- OnkoSight NGS JAK2 reflex to MPL methods
- OnkoSight NGS JAK2 reflex to MPL references 1
- OnkoSight NGS JAK2 reflex to MPL report footer
- OnkoSight NGS JAK2 V617F sequencing report
- OnkoSight NGS JAK2 V617F sequencing report
- OnkoSight NGS MPL sequencing report
- OnkoSight NGS MPL sequencing report
- Opiates confirmation panel, serum
- Pathologist signature, UPE, random urine
- Pathology consult
- Pathology consult panel
- PDGFRB by FISH
- PDGFRB by FISH (global), non NY panel
- Plasma cell dyscrasia IHC analysis panel
- Platelet morphology panel

- Pneumocystis smear, DFA
- Pneumocystis smear, DFA panel
- PNH, PI-linked antigen panel
- Potassium, whole blood, mmol/L
- Protein, 24 hr urine, Bence-Jones panel
- Protein, CSF panel
- Proteinase 3 ab, CU
- PT panel
- PV, JAK2 V617F final diagnosis
- PV, JAK2 V617F reflex result
- PV, JAK2 V617F specimen type
- PV, JAK2 V617F w/ Rfx to JAK2 EXON 12-15 (screening) panel
- Rapid strep screen
- Rapid strep screen panel
- Rasburicase uric acid panel
- RNA Polymerase III ab, units
- RNP ab, ELU/mL
- S. pneumoniae Ag panel, urine
- SC5B-9 complement, P, ng/dL
- SCL-70 extractable nuclear ab, ELU/mL
- Semi-quant IHC, manual, tissue interpretation
- Semi-quant IHC, manual, tissue panel
- Serotonin release assay result
- Serotonin release assay, unfractionated heparin comments
- Serotonin release assay, unfractionated heparin interpretation
- Signatera MTM readout, MTM/mL
- Signatera panel
- Signatera PDF
- Signatera test result
- Signatera third portal ID
- Smith extractable nuclear ab, ELU/mL
- Sodium, whole blood, mmol/L
- Sperm, motile, UA
- Sperm, nonmotile, UA
- Sputum aerobic culture
- Sputum aerobic culture panel
- Sputum culture with gram stain panel
- Surgical site aerobic culture
- Surgical site aerobic culture panel
- Surgical site anaerobic culture
- Surgical site anaerobic culture panel
- Tempus PD-L1 panel
- Tempus PD-L1 report
- Tempus portal
- Tempus xT panel

- Thiopurine methyltransferase (activity profile), RBC panel
- Thiopurine methyltransferase, RBC reviewed by
- Tissue fungus culture
- Tissue fungus culture panel
- Tissue, anaerobic culture panel
- Tissue, anaerobic culture panel comment
- Troponin T delta change interpretation
- Troponin T delta difference
- Troponin T delta, % ng/L
- Urine, aerobic culture panel
- Vitamin B1 (thiamin), WB, nmol/L
- Vitamin B1, whole blood panel
- WBC stain panel, stool
- WBC stain, stool
- WBC/NUC cells, body fluid, /uL
- WBC/NUC cells, fluid, cells/u

Medications

Additions

- AMG 757 invest IV
- ASP1012 invest IV
- AZD5305 invest Oral
- BG-68501 invest Oral
- DB-1311 invest IV
- HGT-2310 invest Intrathecal
- IAM1363 invest Oral
- Idursulfase invest (HGT-2310 invest Intrathecal)
- La Roche-Posay Lipikar AP+ M Triple Repair Moisturizing Cream
- LP-184 invest IV
- MK-5684 invest Oral
- NM32-2668 invest IV
- REC-4881 invest Oral
- Tarlatamab invest (AMG 757 invest IV)

Updates

Medication	Update
AGEN1884 invest IV	New synonym available: Zalifrelimab invest
Belzutifan Oral	New instructions available: Take with or without food.

Medication	Update
BI 907828 invest Oral	New synonym available: Brigimadlin invest
CLN-081 invest Oral	New medication name : CLN-081/TAS6417 invest Oral New synonym available: Zipalertinib invest
eflornithine Oral	New max single dose : 768 mg New instructions available: Take with or without food. New quick sig available.
iptacopan Oral	New max single dose available: 200 mg New instructions available: Take with or without food. New quick sig available.
Luveltamab tazevibulin (STRO-002 invest IV)	New form available: 100 mg recon soln
LY3537982 invest Oral	New form available: 25 mg capsule
PCM-075 invest Oral	New quick sig available. New forms available: <ul style="list-style-type: none"> • 10 mg capsule • 20 mg capsule • 30 mg capsule
PRO1184 invest IV	New synonym available: Rinatabart Sesutecan invest
XmAb20717 invest IV	New synonym available: Vudalimab invest
ZN-c3 invest Oral	New Forms available: <ul style="list-style-type: none"> • 100 mg tablet (test formulation) • 25 mg tablet (test formulation)

Regimen Library

Additions

Eligard Pre-Check Change

The P&T Executive Committee recently voted to approve the pre-check change from Lupron Depot (leuprolide acetate) to Eligard (leuprolide acetate) in prostate cancer regimens.

All applicable regimens have been updated with this content release.

Added

Regimen Name	Diagnosis
Acalabrutinib + Rituximab IV D1,8,15,22 fb D1 Q28D fb D1 Q56D	Lymphoma, Non-Hodgkin (NHL) (Parent)
Daratumumab SQ + Cyclophosphamide IV + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 1 of 2)	Multiple Myeloma (MM)
Methotrexate + Doxorubicin CIV + Cisplatin (MAP) Q7D (Perioperative)	Sarcoma, Bone (Parent)
Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D (Bladder)	Bladder Cancer
Paclitaxel D1,8 + Carboplatin + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D	Breast Cancer
Paclitaxel D1,8 + Carboplatin + Trastuzumab IV + Pertuzumab IV Q21D	Breast Cancer
Paclitaxel IV D1,8,15 + Carboplatin IP Q21D	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Pembrolizumab + Bevacizumab + Cyclophosphamide PO Q21D	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Ruxolitinib + Darbepoetin alfa Q7D (Myelofibrosis)	Myelofibrosis, Myeloproliferative Disorder
Pembrolizumab + Cisplatin D1,8,15 + XRT Q21D (Cervical)	Cervical Cancer
Pembrolizumab Q42D (Flat Dose) (Cervical Maintenance)	Cervical Cancer
Ruxolitinib + Epoetin alfa Q7D (Myelofibrosis)	Myelofibrosis, Myeloproliferative Disorder
Ruxolitinib + Luspatercept-aamt Q21D (Myelofibrosis)	Myelofibrosis, Myeloproliferative Disorder

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include reference updates, drug infusion instruction updates, renaming regimens, premedication template updates and number of cycles.

- All Problems
- Anemia, Hemolytic
- Fallopian Tube Cancer
- Head and Neck Cancer (Parent)
- Hemolytic Uremic Syndrome
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)

- Multiple Myeloma (MM)
- Myasthenia Gravis
- Ovarian and Primary Peritoneal Cancer
- Paroxysmal Nocturnal Hemoglobinuria
- Prostate Cancer

Renames

Previous Name	New Name
Daratumumab SQ + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 2 of 2: Daratumumab SQ only)	Daratumumab SQ + Cyclophosphamide + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 2 of 2: Daratumumab SQ only)
Paclitaxel + Cisplatin Q21D (Head and Neck)	Paclitaxel + Cisplatin Q21D (Head and Neck, Ovarian)

Research

Updates

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 18194		X		
USOR 20270	X			
USOR 20285	X	X		
USOR 20310	X			Now available: USOR 20310 AMG 510 (PO; Daily) + Panitumumab D1,15 + mFOLFOX6 D1,15 Q28D

	Updated Reference Information			Other Changes
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
USOR 21304	X			<p>Now available:</p> <ul style="list-style-type: none"> USOR 21304 Regimen S Carboplatin + Pegylated liposomal doxorubicin + Bevacizumab (D1,15) + TRK-950 (D1,15) Q28D (Treatment Phase) USOR 21304 Regimen S Bevacizumab + TRK-950 Q21D (Maintenance Phase) USOR 21304 Regimen T Paclitaxel (D1,8,15) + TRK-950 (D1,8,15,22) Q28D <p>No longer available: USOR 21304 Regimen Q Ramucirumab D1,15 + Paclitaxel D1,8,15 + TRK-950 D1,8,15,22 Q28D</p>
USOR 21308	X	X	X	
USOR 21386	X		X	
USOR 22002				<p>No longer available:</p> <ul style="list-style-type: none"> USOR 22002 XL092 (PO; Daily) + Nivolumab + Ipilimumab Q21D USOR 22002 XL092 (PO; Daily) + Nivolumab Q28D (Post-Ipilimumab)
USOR 22067	X	X	X	<p>Now available:</p> <ul style="list-style-type: none"> USOR 22067 PRO1184 + Carboplatin Q21D USOR 22067 PRO1184 + Bevacizumab Q21D USOR 22067 PRO1184 + Pembrolizumab Q21D
USOR 22083	X	X	X	<p>No longer available: USOR 22083 CNTY-101 D1,8,15 + IL-2 D2-5,9-12,16-19 D1-22 (Schedule B)</p> <p>Now available: USOR 22083 CNTY-101 D1,8,15 + IL-2 D2-5,9-12,16-19 (Schedule B)</p>
USOR 22087				<p>No longer available:</p> <ul style="list-style-type: none"> USOR 22087 H3B-8800 (RVT-2001) (PO; BID) Q28D USOR 22087 H3B-8800 (RVT-2001) (PO; QD) Q28D
USOR 22090	X	X		
USOR 22198	X			
USOR 22283	X			
USOR 22298	X	X	X	

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 22302	X	X	X	Now available: <ul style="list-style-type: none"> • USOR 22302 Gemcitabine D1,8,15 Q28D • USOR 22302 Gemcitabine D1,8 Q21D • USOR 22302 Paclitaxel D1,8,15 Q28D • USOR 22302 Pegylated Liposomal Doxorubicin Q28D • USOR 22302 Topotecan D1,8,15 Q28D • USOR 22302 Topotecan D1-5 Q21D
USOR 23025	X			
USOR 23065	X	X		
USOR 23074	X			No longer available: USOR 23074 SGN-B6A D1,8 Q21D Now available: USOR 23074 SGN-B6A D1,15 Q21D
USOR 23102		X		
USOR 23152	X	X		
USOR 23160	X	X	X	
USOR 23172		X	X	No longer available: <ul style="list-style-type: none"> • USOR 23172 Consolidation Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D • USOR 23172 Extension Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D Now available: <ul style="list-style-type: none"> • USOR 23172 Cohort A Consolidation Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D (Esophageal, EGJ) • USOR 23172 Cohort A Extension Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D (Esophageal, EGJ) • USOR 23172 Cohort B Consolidation Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D (Pancreatic) • USOR 23172 Cohort B Extension Phase Futibatinib (PO; Daily) + Pembrolizumab Q42D (Pancreatic)
USOR 23261	X	X		

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
ADAMTS13, recombinant-krhn IV	J3590 per: <ul style="list-style-type: none"> • 500 units • 1500 units
Anthrax vaccine adsorbed, adjuv IM	90581 per 0.5 mL
Efgartigimod-hyaluronidase-qvfc Subcutaneous	J9334 per 0.01112 mL
Exagamglogene autotemcel IV	J3590 per 4x 10e6 CD34+ cells
Hyaluronate Sodium, Stabilized Intra-Articular	J7327 per: <ul style="list-style-type: none"> • 88 mg • 4 mL
ibuprofen sodium-acetaminophen IV	J3490 per 1000 mg
kit for of prep Tc-99m-albumin IV	Q9969 per: <ul style="list-style-type: none"> • 7.4 MBq • 0.025 mCi
Lovotibeglogene autotemcel IV	J3590 per 3x 10e6 CD34+ cells
Nedosiran Subcutaneous	J3490 per: <ul style="list-style-type: none"> • 80 mg • 128 mg • 160 mg
Omalizumab Subcutaneous Auto-Injector	J2357 per 5 mg
Pegfilgrastim-cbqv Subcutaneous (via wearable injector)	Q5111 per 0.5 mg
Tranexamic Acid IV	J3490 per 100 mg